Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model by Roberson Erik D, Scearce-Levie Kimberly, Palop Jorge J, Yan Fengrong, Cheng Irene H, Wu Tiffany, Gerstein Hilary, Yu Gui-Qiu, Mucke Lennart in Science (New York, N.Y.) (2007).

[PMID: 17478722] PubMed


Many potential treatments for Alzheimer's disease target amyloid-beta peptides (Abeta), which are widely presumed to cause the disease. The microtubule-associated protein tau is also involved in the disease, but it is unclear whether treatments aimed at tau could block Abeta-induced cognitive impairments. Here, we found that reducing endogenous tau levels prevented behavioral deficits in transgenic mice expressing human amyloid precursor protein, without altering their high Abeta levels. Tau reduction also protected both transgenic and nontransgenic mice against excitotoxicity. Thus, tau reduction can block Abeta- and excitotoxin-induced neuronal dysfunction and may represent an effective strategy for treating Alzheimer's disease and related conditions.

[ hide abstract ]

Discussed In Paper


Rx Annotations

No dosing information annotated.